HIMS Q3 Earnings Call Highlights Marketing Reset and Margin Pressure - Zacks Investment Research
HIMS Q3 Earnings Call Highlights Marketing Reset and Margin Pressure - Zacks Investment Research(摘要待生成)
Hims & Hers Health (HIMS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Zacks Investment Research
Hims & Hers Health (HIMS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Zacks Investment Research(摘要待生成)
Hims & Hers Health Stock Crashes After Earnings: Is Now the Time to Buy? - Yahoo Finance
Hims & Hers Health Stock Crashes After Earnings: Is Now the Time to Buy? - Yahoo Finance(摘要待生成)
HIMS Stock Plummets 15% After Weak Q4 Guidance - GuruFocus
HIMS Stock Plummets 15% After Weak Q4 Guidance GuruFocus
Hims & Hers (HIMS) Q3 2026 Earnings Call Transcript
Hims & Hers (HIMS) Q3 2026 Earnings Call Transcript(摘要待生成)
What Hims & Hers Health (HIMS) Said on Its Q3 Earnings Call - Yahoo Finance
What Hims & Hers Health (HIMS) Said on Its Q3 Earnings Call - Yahoo Finance(摘要待生成)
Hims & Hers Projects Full-Year Revenue Below Estimates
Hims & Hers Health expects full-year revenue of $3.13 billion to $3.15 billion, below the $3.21 billion estimate. [[fact-zmqeve50e]] The company reported third-quarter revenue of $890.4 million, slightly below the $892.8 million estimate. [[fact-129cvffk2]] It reported a third-quarter loss of 14 cents per share, compared with earnings of 6 cents per share a year earlier. [[fact-o40q9p886]]
Hims & Hers Health, 8-K (2.02, 8.01, 9.01): reported results of operations
Hims & Hers reported Q3 2026 revenue of $890.4 million, up 49% year over year, and 2.788 million subscribers, up 13%; it forecast full-year revenue of $3.13–$3.15 billion and Adjusted EBITDA of $257–$277 million.
HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs - Zacks Investment Research
HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs - Zacks Investment Research(摘要待生成)
Hims & Hers Health, 8-K (5.02): director or officer change
Hims & Hers expanded its board from nine to ten and appointed Dr. Andrew Huberman, who will receive $50,000 annual cash retainer and $250,000 annual equity; separate two-year advisory and up-to-three-year podcast marketing agreements provide annual fees of $3.5 million and $5 million, respectively.
Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement
Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement(摘要待生成)
What Should Hims & Hers Health, Inc. Investors Know After 14.73% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline
What Should Hims & Hers Health, Inc. Investors Know After 14.73% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline(摘要待生成)
MONDAY INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline
MONDAY INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline(摘要待生成)
HIMS Deadline in 3 Days: Hims & Hers Health, Inc. (HIMS) Class Action Lawsuit Seeks Recovery for Investors; November 2, 2026 Deadline- Contact Kessler Topaz Meltzer & Check, LLP
HIMS Deadline in 3 Days: Hims & Hers Health, Inc. (HIMS) Class Action Lawsuit Seeks Recovery for Investors; November 2, 2026 Deadline- Contact Kessler Topaz Meltzer & Check, LLP(摘要待生成)